Join
Live feed
·
PRReleasevia Quantisnow
Exelixis Inc. logo
Genmab A/S logo
Oncolytics Biotech Inc. logo
+2

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

ByQuantisnow·Wall Street's wire, on your screen.
EXEL· Exelixis Inc.GMAB· Genmab A/SONCY· Oncolytics Biotech Inc.RVMD· Revolution Medicines Inc.LLY· Eli Lilly and Company
Health Care
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda | Quantisnow